3 minutes agoSecond generation of anti - vaccines CO VID-19, trials on people in the third quarter of this year
Periskopi(5 years ago)
(5 years ago)Second generation of vaccines against CO VID-19, developed by CureVac and GlaxosSmithKline, designed to protect from various variants of the coronary, produced a high level of immune response during rat testing, companies said today. It's a single dose of vaccine using m technology. ARN similar to successful vaccine [...]
Second generation of vaccines against CO VID-19, developed by CureVac and GlaxosSmithKline, designed to protect from various variants of the coronary, produced a high level of immune response during rat testing, companies said today.
It's a single dose of vaccine using m technology. ARN similar to the successful vaccine developed by Pfizer/ B ONTech and Moderna and the start of clinical test vaccines in people are expected in the third quarter of this year, Reuters reports.
The immune mice with a vaccine called CV2CoV showed a quick and strong immune response to the strains of the virus discovered in Denmark, Great Britain and South Africa.
For a successful fight against COVID-19, we will need different vaccines in the long-term plan and we should be able to respond effectively to new variants,” said GlaxosmithKline President Roger Connor.
